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Abstract
The purpose of the study project was to compare a nonspecific substance screening
questionnaire with a well validated, evidence-based substance screening tool designed
specifically for the pregnant population Evidence has shown use of an evidence-based
screening tool improves maternal and fetal outcomes and reduces the risk of missed cases,
stereotyping, and stigma. This study project utilized the social learning theory model, which
defines human behavior as a reciprocal, continuous interaction among cognitive, behavioral,
and environmental determinants. A pilot observational study project was conducted within a
focal organization in a specified women’s health clinic over a 12-week period comparing
their currently used nonspecific substance screening questionnaire with the use of a wellvalidated, evidence-based screening substance screening tool. This study project
demonstrated that the SURP-P tool, compared to the EPIC questionnaire, captures a
significantly greater number of women in pregnancy at risk for substance abuse. It is
important that clinicians are fully trained on this tool and understand how to objectively
interpret the results to provide proper follow-up and management for those identified at risk
for substance abuse. Adopting this tool within this women’s specialty program will
contribute to improved maternal and fetal outcomes. Every woman has the right to be cared
for equally and comprehensibly, thus preventing stigmatization, discrimination, and
marginalization.

Keywords: pregnancy, suboxone treatment, screening, referral, substance use, barriers,
facilitators, buprenorphine, dependence, fetus, harm, methadone, opioid use disorder,
intervention, opioid agonist medication, prenatal exposure, substance use disorder, addiction,
treatment outcomes pregnancy
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CHAPTER ONE: INTRODUCTION AND BACKGROUND
Problem Statement
It has been well documented that maternal mortality rates are on the rise in America.
According to the Centers for Disease Control and Prevention (CDC, 2020), about 700
women die each year from pregnancy or birth complications. This death rate has steadily
increased since the CDC began monitoring death rates related to pregnancy in 1987. A
pregnancy-related death is considered any woman who has died within 1 year of the end of
pregnancy from any cause related to the pregnancy or its management (CDC, 2020). This
measurement does not include accidental or incidental causes. Per 100,000 births, the
maternal death rate has increased from 7.2 deaths per year in 1987 to 16.9 deaths per year as
of 2016 (CDC, 2020).
Recent research shows that maternal deaths are largely related to the growing
population of Americans who suffer from multiple co-morbidities. These co-morbidities lead
to higher risk pregnancies and outcomes with incidents resulting in death. Of the various comorbid conditions, the most common are hypertension, diabetes, and heart disease (CDC,
2020). Research also demonstrates that significant variability in the risk of death relates to
race or ethnicity. For example, according to the CDC (2020), African American women are 3
to 4 times more likely than White women to die from pregnancy-related causes. The same
disparity exists among Native American and Native Alaskan populations as well; these
populations are 2.5 times more likely than Whites to experience a pregnancy-related death
(CDC, 2020).
Significant disparities have been observed between minority and White populations in
the United States. Some of these, identified by the American College of Physicians (2010),
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are: lack of insurance coverage or income; limited or no access in rural or urban
communities; lack of training for best practices; determinants created by inequities (such as
education, employment, transportation, and housing) related to public policy, laws, and
racism; and clinicians ignoring concerns of minority patients, resulting in poor care. Of these
findings, what is of most concern is growing evidence related to cultural insensitivity, which
suggests a direct correlation between a patient’s race or ethnicity and implicit and explicit
biases among clinicians that negatively impact the quality of care being delivered to them.
The CDC (2020) has claimed that as many as 60% of maternal deaths are
preventable. This means two out of every three deaths could have been avoided. This is a
shocking and significant finding. Preventable disparities and inequities negatively impact the
health of patients. As the U.S. population continues to grow and become more diverse, the
healthcare industry must be able to keep up. It must become increasingly aware of the needs
of this complex and evolving population. It is evident that in order to improve maternal
health, reducing disparities and eliminating inequities is imperative.
To address the problem of increasing maternal mortality rates, approximately $351
million in funding was approved by the U.S. Department of Health and Human Services
(HHS) for the Maternal, Infant and Early Childhood Home Visiting Program (MIECHV).
These funds are to be utilized by grantees to develop and implement programs to meet the
needs of their at-risk communities to improve maternal health (HHS, 2019). The focal
organization of this study project has been awarded $2 million in a grant through MIECHV
to develop its own programs. This award was achieved in part because the focal organization
is considered a not-for-profit, with patients primarily comprised of minority groups. The
focal organization currently does not have a program in place to treat substance abuse in the
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pregnant population. The grantor has emphasized that with the award, a substance use
disorder treatment program should be considered within the women’s specialty care program
to meet the needs of this at-risk community.
Study Project Purpose/PICOT
Within the women’s specialty program in this study project, the first opportunity to
screen a pregnant patient for substance abuse is at the initial obstetric visit when the patient
first seeks care. The women’s specialty program currently does not use an evidence-based
universal screening tool to identify and manage pregnant women at risk for substance abuse.
Instead, they use an electronic medical record (EMR) computer system known as EPIC,
utilizing the system’s basic and generic non-specific screening questionnaire for substance
abuse, leaving management somewhat subjective and up to each clinical provider’s discretion
based on their findings. According to American College of Obstetrics and Gynecology
(ACOG) and the World Health Organization (WHO), universal screening with an evidencebased substance screening tool contributes to improved maternal and fetal outcomes. In
addition, use of an evidence-based screening tool reduces the risk of missed cases,
stereotyping, and stigma (ACOG, 2017; WHO, 2014). The purpose of this study project was
to screen pregnant women seeking obstetric care during their initial obstetric visit within a
defined women’s health clinic within the focal organization by using the Substance Use Risk
Profile-Pregnancy (SURP-P), a well-validated, evidence-based tool compared to use of the
current non-specific substance abuse screening questionnaire (EPIC questionnaire) to
identify a higher percentage of women with increased risk of substance use over a 12-week
period.
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Objectives and Goals
The aim of this study project was to pilot the use of an evidence-based, well-validated
universal substance abuse screening tool to determine whether a higher percentage of
pregnant women could be identified as at-risk for substance abuse within the defined clinic.
This was achieved by comparing and evaluating the EPIC questionnaire, the current nonspecific substance abuse screening questionnaire, and the SURP-P tool. The SURP-P tool has
been endorsed by both ACOG and WHO and is specifically validated for screening for
substance abuse among the pregnant population. The goal of the study project was to
encourage the focal organization women’s specialty program to adopt a well-validated,
evidence-based substance screening tool, with the overall goal of improving maternal and
fetal outcomes through identifying high-risk patients early and offering appropriate treatment
for substance-dependent patients seeking obstetric care.
Scope of the Study Project
This study project was carried out with the intent to establish which screening method
would be most appropriate to use not only within this clinic but universally within the focal
organization’s women’s specialty program. Three screening tools were considered for
comparison with the questionnaire: the Substance Use Risk Profile-Pregnancy (SURP-P), the
National Institute on Drug Abuse Quick Screen-Modified Alcohol, Smoking and Substance
Involvement Screening Test (NIDA-Modified ASSIST) and the 4P’s Plus. All three have
been endorsed by both ACOG and WHO for use in screening for substance abuse. Although
the NIDA-Modified ASSIST was endorsed by ACOG and WHO, it has not been specifically
validated for use amongst the pregnant population, unlike both the SURP-P and the 4P’s
Plus. The 4P’s Plus was found to have copyrights with specific licensing requirements that
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were costly and required extensive training for use. For that reason, the SURP-P was chosen
for this study project because this tool did not share the same complexities as the other two
tools. This tool is both a well-validated substance abuse screening tool specific to the
pregnant population, and it does not have any cost barriers associated with its use.
Assumptions
The first assumption of this study project was that the SURP-P tool was appropriate
and specific to the population being screened. Secondly, it was assumed that the SURP-P tool
was implemented properly by the staff surveying the patients. Lastly, it was assumed that
participants were more likely to answer the SURP-P tool questions honestly than the
questions with the EPIC questionnaire.
Significance of the Study Project
This study project expanded current practice within the focal organization’s women’s
specialty program of how substance abuse screening is conducted amongst the pregnant
population. This study project emphasized the importance of utilizing a well-validated,
evidence-based universal substance abuse screening tool in pregnancy, which is necessary to
identify pregnant women at-risk for substance abuse to give them proper evidence-based care
and management.
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CHAPTER TWO: REVIEW OF LITERATURE
Evidence-Based Substance Abuse Screening Tools
Several articles pertaining to screening tools for identifying pregnant women at risk
for substance abuse were reviewed for this study. The first of these by Smith et al. (2010)
details the origins of the NIDA Quick Screen tool and is titled “Single-Question Screening
Test for Drug Use in Primary Care.” The purpose of this study was to validate the use of the
single-question screening tests now known as the NIDA Quick Screen for use as a universal
screening for drug use and drug use disorders in primary care. This screening tool is the basis
for a slightly modified NIDA tool known as the NIDA-modified ASSIST. It was slightly
modified by the WHO and is now recommended by both WHO and ACOG as a substance
abuse screening tool for the pregnant population. A quantitative randomized control trial was
done in 2009 with 286 participants between the ages of 21 and 86 in an urban safety-net
hospital primary care clinic at an academic medical center. Fifty-four percent were women
with a median age of 49 years, with most participants (63%) identified as Black. Only 17%
identified as White, and 16% identified as Hispanic. 78% had completed high school, but
only 14% had completed college. They were screened using a single screening questionnaire
for drug use and drug use disorders. The 10-item Drug Abuse Screening Test (DAST-10), an
established tool widely used in criminal and detoxification settings, was administered for
comparison.
Smith et al.’s (2010) study demonstrated that the single-question screening
questionnaire test had a 100% sensitivity and was 73.5% specific for detection of drug use
disorder. In reference to the DAST-10, test characteristics were similar. Drug use was also
determined by oral fluid testing to demonstrate validity. The study produced significant
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reliability scores. The single-question screen accurately identified a broad spectrum of drug
use in the primary care setting. These findings support the use of brief, reliable screening
tools for the identification of drug use. Although Smith et al.’s (2010) study was not
conducted on the pregnant population, it did demonstrate significant reliability.
The second article reviewed was by Yonkers et al. (2010) and was titled “Screening
for Prenatal Substance Use.” The purpose of the study was to report on the development of a
questionnaire used to screen for substance abuse in pregnant women that is now known as
the SURP-P tool. This is a hybrid of three previously available screening tools—TWEAK
(alcohol screening), 4P’s Plus, and Addiction Severity Index—and contains two domestic
violence questions. The performance of this tool was compared to the performance of other
measuring tools. Patients were administered the modified TWEAK questionnaire, the 4P’s
Plus questionnaire, items from the Addiction Severity Index, and two questions about
domestic violence (N = 2684). The sample was divided into training (N = 1610) and
validation (N = 1074). Responses were recorded with a three-item Substance Use Risk
Profile scale. The subsample was validated by comparing it with the modified TWEAK and
various scoring algorithms of the 4P’s Plus. Several established tools were also used in
comparison and to allow for an effective and diverse tool that eliminated redundancy from
using varying tools to do an assessment.
Yonkers et al.’s (2010) study found that low-risk populations demonstrated a high
predictive value for substance use (Akaike’s Information Criterion = 579.75, Nagelkerke R2
= 0.27), with high sensitivity (91%) and specificity (67%). The high-risk population had
lower sensitivity (57%) but higher specificity (88%). The study demonstrated that the SURPP tool may be used to detect a range of substance abuse. This cohort study was large (N =
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2684), which is important to analyze risk of use among a diverse population. This study
showed that a simple scale tool such as the SURP-P can be used and has good sensitivity and
specificity. This scale can be utilized for both high and low risk populations. Screening and
scoring with the SURP-P were simple yet effective compared to the other tools.
The third article reviewed was by Coleman-Cowger et al. (2019) and was titled
“Accuracy of Three Screening Tools for Prenatal Substance Use”. The purpose of the study
was to identify problematic drug use in pregnancy via screening. No specific substance-use
screener had been universally recommended for use in pregnancy. This study compared and
validated the use of three screening tools as recommended by ACOG and the WHO: the
NIDA Quick Screen-ASSIST, the SURP-P, and the 4P’s Plus. All three had previously been
validated across several populations. Both the SURP-P and the 4P’s Plus were specifically
validated with a population of pregnant women; however, the NIDA Quick Screen-ASSIST
was not. Previous studies on pregnancy found the 4P’s Plus screening had 87% sensitivity
and 76% specificity, and the SURP-P had 91% sensitivity and 67% specificity for low-risk
populations, with a lower sensitivity of 57% and higher specificity 88% for those at high risk.
In this study, compared to the NIDA Quick Screen-ASSIST, the SURP-P and 4P’s Plus had
higher sensitivity with negative predictive values. This demonstrated these two tools to be
ideal for clinical use for prenatal substance abuse screening.
Of the 500 participants in Coleman-Cowger et al.’s (2019) study, 494 received at
least one of the three screening tools. Four hundred eighty-five received the NIDA Quick
Screen-ASSIST, 491 received the 4P’s Plus, and 492 received the SURP-P. The NIDA Quick
Screen-ASSIST had a sensitivity of 79.7% and specificity of 82.8%. The SURP-P had a
sensitivity of 92.4% and specificity of 21.8%. The 4P’s Plus had a sensitivity of 90.2% and
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specificity of 29.6%. Four hundred fifty-three were retested for reliability, and 47 were
unable to be followed up with. The test-re-test reliability was 0.84, 0.77, and 0.79
respectively for the 4P’s Plus, NIDA Quick Screen-ASSIST, and SURP-P. A large sample
size of 500 participants gave a confidence of 95% that a false-negative rate in this population
was under 10%. Five hundred would be considered enough for determining significant
disagreement between any pair of survey results. There were differences in validity indices
by age and race but none for trimester, demonstrating good generalizability. Gold standard
urine and hair testing were performed to measure screening validity.
When utilizing a screening tool, it is important the tool demonstrates a high
sensitivity to ensure proper screening is being conducted. This study demonstrated that
SURP-P and the 4P’s Plus tools had higher sensitivity and negative predictive values than the
NIDA Quick Screen-ASSIST tool, making these two tools more ideal substance abuse
screening tools to utilize with the pregnant population. The NIDA Quick Screen ASSIST had
highest specificity but a low sensitivity. This study confirmed prior studies in that both the
SURP-P and 4P’s Plus were found to be highly sensitive and recommended for use in all
trimesters of pregnancy and with all racial groups. Establishing the use of a well-validated
substance screening tool is essential to encourage proper screening in the clinical setting
among this vulnerable population.
Management Approach to Substance Abusing Women
This literature review also examined several articles on the proper management of
positively identified pregnant women with substance abuse. The first article reviewed was by
Tuten et al. (2019) and was titled “The Impact of Early Substance Use Disorder Treatment
Response on Treatment Outcomes Among Pregnant Women with Primary Opioid Use”. The
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purpose of the study was to assess the impact of early patient response on treatment
utilization and substance abuse among pregnant participants enrolled in substance use
disorder treatment (SUD). The study was specifically designed to assess the efficacy of
tailored treatment intensity based on participant early treatment response. This was a
quantitative secondary data analysis of 194 patients enrolled in a sequential multiple
assignment randomized trial at the Center of Addiction and Pregnancy in Baltimore,
Maryland. Participants were between the ages of 18 and 46 and entered treatment at
gestational age 34 weeks or less with a single fetus. Participants excluded from the study
were those without opioid use (N = 22) and those who had an abortion (N = 4). Ninety-two of
the patients were early treatment responders (TRs) and 102 were early treatment nonresponders (TNRs). TRs and TNRs were compared on demographic, psychosocial, and SUD
treatment outcome measures for utilization of opioids, cocaine, and any other substance at 1
and 2 months after enrollment in the full sample.
Findings showed that TNR participants reported more days of use of multiple
substances during the 30 days before treatment enrollment. Significant differences were
observed on SUD treatment outcome measures for the two groups. TR participants attended 2
additional weeks of treatment before infant delivery compared with TNR participants. TR
participants also had significantly lower rates of substance use at both 1 and 2 months
relative to TNR participants. These significant findings are extremely useful for the current
study, in that they show the earlier treatment interventions are done, the more likely is
utilization of the treatment program, and higher likelihood of patient adherence leads to
improved maternal and fetal outcomes. This study further validated that it is critical to
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properly screen women for early identification of substance abuse and enroll them in proper
treatment in a substance abuse program once identified.
The second article addressed the management of women with opioid addiction who
were treated during their pregnancy with either methadone or buprenorphine. The article
reviewed was by Kaltenbach et al. (2018) and was titled “Prenatal exposure to methadone or
buprenorphine: Early childhood developmental outcomes”. The purpose of the study project
was to evaluate early childhood developmental outcomes of children exposed to methadone
or buprenorphine in utero. This was a randomized controlled trial of 96 children and their
mothers who received opioid-agonist pharmacotherapy during pregnancy. The children were
assessed from age 0 to 36 months. The study project assessed children’s growth parameters,
cognition, language abilities, sensory processing, and temperament. Maternal perceptions of
parenting stress, home environment, and addiction were also part of the study project, which
was conducted at hospital sites by blind trained examiners (meaning they did not know which
medication treatment participants received). The study project found no more harmful effects
from receiving treatment in pregnancy than not receiving treatment. Previous studies have
indicated that buprenorphine may be superior to methadone when considering neonatal
outcomes; however, this study project did not find any significant difference between the
two. Children between 3 and 36 months of age were within range for normal development,
including physical and cognitive growth. This also held true for temperament, language
abilities, and sensory processing, and no significant declines in the children were found over
time. The study also demonstrated that neonatal abstinence syndrome (NAS) severity did not
have any significant impact on the children’s physical or cognitive growth.
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In their research on the mothers, Kaltenbach et al. (2018) found that although the
children presented within normal limits of development, mothers’ perceptions of difficulties
with their children increased notably over time. It was unclear if this was due to this
population exhibiting higher levels of stress around typical child behaviors or whether the
children exhibited more challenging behaviors or perhaps both. In contrast, home assessment
scores showed consistency, in that these children had a more enriched home environment.
This suggests that developmental risks may be more related to the parent‒child relationship
than adverse effects from treatment during the mother’s pregnancy.
This information is important because it shows that both treatment regimens of
methadone and buprenorphine can be considered. It is important to note there could be
variation in cost or accessibility to either treatment. This study also demonstrated the
importance of assessment and the long-term management considerations of the mother’s
coping and paternal competence. These results suggest that those with a history of drug abuse
could have poorer coping skills than those without a history of drug abuse.
The third article reviewed was by Peles et al. (2017) and was titled “Newborn
Birthweight of Pregnancy Women on Methadone or Buprenorphine Maintenance Treatment:
A National Contingency Management Approach Trial”. The purpose of the study was to
assess whether an escalating incentive contingency-management approach may contribute to
better newborn birth weights in opioid-abusing women on methadone treatment. The
researchers noted that although methadone was the gold standard of care, low birth weights
were reported, especially in those who became pregnant before admission into a program.
The study was a quantitative randomized controlled trial of patients currently enrolled in the
Israeli methadone/buprenorphine maintenance treatment program. The study had 35
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participants with 46 pregnancies during the study period. Nineteen participants were placed
in the contingency-management program and 16 in the standard program. The contingency
program offered coupons escalating in value depending on the reduction of drug use,
cigarette consumption, and alcohol consumption.
No difference was found in newborn outcomes between the two groups. The findings
did show new enrollees in the incentive program had an improved birth weight, which was in
line with the hypotheses. However, this was not statistically proven due to the small,
unbalanced study groups. What was most notable, however, was that the findings showed
that frequency of reinforcement is related to efficacy of the intervention. This demonstrated
that if clinicians are not consistently monitoring patients for drug abuse, it is likely patients
will continue their substance abuse undetected by their clinicians. This information is
important to the current study in that it confirms the need for evidence-based, well-validated
screening and consistent assessment and management in this population.
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CHAPTER THREE: THEORETICAL MODEL AND METHODOLOGY
Theoretical Model
This study project utilized the social learning theory model, an evidence-based
approach developed by psychologist Albert Bandura (1977). This model was appropriate for
this study project because it focuses on vicarious, symbolic, and self-regulatory processes
and their influence on psychological functioning (Bandura, 1977). The model defines human
behavior as a reciprocal continuous interaction between cognitive, behavioral, and
environmental determinants, and it defines learning as a cognitive process within a social
context. According to the model, learning occurs by observing both behaviors and their
consequences. Through observation, a thought, affect, or behavior can be adapted or taught
through the self-regulatory process. In summary, this model emphasizes that humans can
learn through observation and imitation.
As summarized in Figure 1, four basic principles comprise the social learning theory
model (Bandura, 1977):
•

Attention: Must be able to pay attention to the model. To influence a behavior,
attention to the behavior being observed and its consequences is extremely
important.

•

Retention: Must be able to remember the behavior. It is important to internalize
the information into memory. How well recall takes place influences whether the
behavior is later imitated.

•

Reproduction: Must be able to replicate the behavior. Mental and physical
practice often improves replication of the behavior.
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•

Motivation: Must want to replicate the behavior. Humans are typically motivated
by observing consequence others receive.

Figure 1
Social Learning Theory

Conceptually, this model lends itself to this study project in that substance abuse is
thought to be not only a chemical dependence but also a behaviorally or socially influenced
condition. The Australian Government Department of Health (AGDH) has adopted the social
learning theory model for use in their policy management for substance abuse. Utilizing this
model, AGDH (2004) summarized substance abuse with the following key points:
•

Finding pleasure in the activity creates risk of developing dependence.

•

Dependence is a learned behavior related to conditioning, modeling, and thinking
about the substance.

•

Dependence exists in degrees. The higher the degree of dependence, the greater
the negative feelings experienced in its absence.
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•

The compulsion of wanting to engage in the activity although one knows he or
she shouldn’t be is the hallmark sign of addiction.

•

Behaviors become erratic with increased desire to engage in something he or she
knows they shouldn’t.

•

Addictive behavior is only terminated when the individual makes the decision that
the risk outweighs the benefit of substance use.

Methodology
This pilot observational study project was conducted over a 12-week period to
compare the focal organization’s women’s specialty program’s current nonspecific substance
screening questionnaire (EPIC questionnaire) with a well-validated, evidence-based
screening tool designed specifically for the pregnant population (SURP-P). Each patient at
this clinic seeking initial obstetric care was given the opportunity to participate in the study
project. If eligibility criteria were met at time of rooming, the patient was invited to take part
in the study project. Eligibility assessment and invitations were conducted by one consistent
nursing staff member within the specified women’s health clinic. If a patient expressed
interest while in their private clinic room, the staff member provided them all the necessary
information to join the study project in a written packet format.
All information was printed and placed in the same order for each patient. Each
packet was numerically paired to ensure each document was completed by the same patient.
The first document was the informed consent cover letter for an anonymous survey (see
Appendix A). The second document was the SURP-P tool (see Appendix B). The third
document was the current non-specific EPIC questionnaire (see Appendix C). The patient
was allotted all the time they needed to complete the surveys. The documents were tracked
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by numerically paired data to ensure that consent and surveys were completed by the same
patient. A comparison of this data evaluated the percentages and concordance and
discordance between the two methods in terms of who screened negative and positive on
each.
Statistical Analysis
Both Fisher’s exact test and McNemar’s test were utilized to analyze the data.
Fisher’s exact test is generally used to assess the significance of the association between two
nominal variables (VassarStats, n.d.a). It was used in this study project with the SURP-P tool
and the EPIC questionnaire as the two possibly associated categorical variables. McNemar’s
test is usually adopted to assess the statistical significance of differences between two
percentages that are paired (VassarStats, n.d.b). This test was utilized in this study project to
determine whether there were statistically significant differences in the percentages.
Ethical Issues
No ethical issues were expected to arise from utilizing staff to screen patients, as no
extra workload was imposed on them. The screening process was integrated into the nursing
staff’s current workflow. There were several areas of concern regarding bias in the study
project. The staff member conducting the screening could have held bias against women with
substance abuse. Lack of transparency by each of the patients who were surveyed could have
introduced bias. As Reddy et al. (2017) identified in a study project on opioid use in
pregnancy, women may choose not to disclose their history of use due to concerns about
social stigma or legal ramifications as well as mistrust of the healthcare provider. To address
these possible sources of bias, the author ensured all staff were trained adequately and that a
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disclosure was given to both staff and patients regarding the intent of the study project and
patient’s rights to privacy within the study project.
Setting
The study project took place at a specific women’s specialty clinic within the focal
organization in Espanola, New Mexico. This clinic is exclusive to women’s health and serves
women seeking obstetric care. The location surrounding this clinic is considered a rural
community.
Population
For the purpose of this study project, predefined inclusion criteria were necessary.
These included: pregnant seeking initial obstetrical care at the specified clinic, aged 18 years
or older, and able to speak and read English to obtain informed consent. If these eligibility
criteria were met, the patient was invited to participate in the study project.
Data Protection Plan
To ensure patients’ sensitive information was protected during the study project, data
were de-identified on the surveys and only tracked numerically. Collected data were then
extracted to a collection spreadsheet. The electronic file was accessible only to the principal
investigator and was housed on an encrypted computer. The written, numerically paired
packets were locked in a drawer in the investigator’s office. These will be stored in this
manner for 7 years, as required by both the University of New Mexico and the focal
organization’s IRB committee. At the end of this time, the packets will be placed in a
HIPAA-compliant shredding bin for document destruction.
Timeline
The timeline for this study project was:
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I. Planning and development: October 2020–October 2021
a. Permission from the originator of the SURP-P tool (see Appendix D)
b. Proposal review and approval by chair and University of New Mexico
College of Nursing
c. Presentation of study project to the focal organization’s specialty clinic in
Espanola, New Mexico
d. Letter of support from the Espanola OB/GYN Medical Director (see
Appendix E)
e. IRB application 21-201 submitted 4/9/2021; approval granted 09/08/2021
f. Preparation and arrangement of nursing staff training
II. Study project implementation: 11/07/2021–02/04/2022
a. Collection of data
b. Initial data analysis
III. Data analysis: 12/01/2021‒04/30/2022
a. Review of data collection
b. Statistical analysis with the University of New Mexico College of Nursing
statistician
c. Summary of findings and discussion
d. Submission of final analysis to the committee
e. Presentation of study project findings to the committee and the University
of New Mexico College of Nursing
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Budget
No costs were anticipated for this study project due to the nature of its design. The
SURP-P tool was a free downloadable tool. Nursing staff were adequately trained on how to
administer the SURP-P tool, and the study project process coincided within their already-inplace rooming and assessment process. The focal organization donated the time, training, and
supplies needed to conduct the study project.

21
CHAPTER FOUR: RESULTS AND DISCUSSION
Results
During this 12-week study project, 62 participants completed the surveys. Fisher’s
exact test and McNemar’s test were utilized to make several assessments of the two
screening methods. To assess the positive and negative results, three categories had to be
analyzed in the SURP-P tool and two categories in the EPIC questionnaire. This was due to
the fact that the SURP-P tool defines its categories as levels of risk based on a scoring system
resulting from the patient’s response. Per the guidelines of the tool, a “yes” response gives a
score of 1 and a “no” response gives a score of 0. A 0 score indicates a low level of risk, a 1point score indicates a moderate level of risk, and a 2- to 3-point score indicates a high level
of risk (or affirmative positive). In contrast, the EPIC questionnaire only utilizes either
negative or positive results. For comparison in this study project, the SURP-P tool low-risk
category was considered equivalent to a negative EPIC result, and the SURP-P moderate or
high-risk categories were considered equivalent to a positive EPIC result.
For the Fisher’s exact test, a two-row by three-column table was created to calculate
the necessary comparison percentages. To describe differences in screening rates between the
two methods, the following percentages were calculated: (a) those who screened EPIC
negative and SURP-P low, (b) those who screened EPIC positive and SURP-P low, (c) those
who screened EPIC negative and SURP-P moderate, (d) those who screened EPIC positive
and SURP-P moderate, (e) those who screened EPIC negative and SURP-P high, and (f)
those who screened EPIC positive and SURP-P high. As shown in Table 1, the surveys
produced a count of 13 for those who screened EPIC negative and SURP-P low, 0 for those
who screened EPIC positive and SURP-P low, 17 for those who screened EPIC negative and
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SURP-P moderate, 7 for those who screened EPIC positive and SURP-P moderate, 13 for
those who screened EPIC negative and SURP-P high, and 12 for those who screened EPIC
positive and SURP-P high.
Table 1
Total Survey Count

low
EPIC

neg
pos

SURP-P
mod
high
13
17
0
7
13
24

13
12
25

43
19
62

Based on these counts, as demonstrated in Figure 2, the following percentages were
calculated: EPIC negative and SURP-P low resulted in 21%, EPIC positive and SURP-P low
resulted in 0%, EPIC negative and SURP-P moderate resulted in 27%, EPIC positive and
SURP-P moderate resulted in 11%, EPIC negative and SURP-P high resulted in 21%, and
EPIC positive and SURP-P high resulted in 19%.
Figure 2
Percentages
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Figure 3 shows the percentages of those who screened EPIC positive versus those
who screened SURP-P moderate, as well as those who screened SURP-P high and those who
screened either SURP-P moderate or high. Only 31% of those utilizing the EPIC
questionnaire screened positive, as compared to 39% of those who screened SURP-P
moderate and 40% of those who screened SURP-P high. Overall, 79% of those utilizing the
SURP-P tool screened either moderate- or high-risk as compared to what was captured by the
EPIC questionnaire.
Figure 3
Positive Screening

In considering the association between the two methods, it was hypothesized that a
significant association would exist between SURP-P and EPIC, as both methods attempt to
screen for the same underlying risk. This association was assessed by Fisher’s exact test with
the Freeman-Halton extension. This gave a p value of .006, which indicated there was a
significant association between the SURP-P tool and the EPIC questionnaire.
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McNemar’s test was used to make exact binomial probability calculations, given that
the total number of discordant observations were equal to or less than 1000. For these
calculations, two hypotheses were made. First, it was assumed there would be directional
discordance with more EPIC negative and SURP-P high pairs than EPIC positive and SURPP low/moderate pairs. As shown in Table 2, the survey count showed EPIC negative and
SURP-P high at 13, while EPIC positive and SURP-P low/moderate had a count of 7.
Table 2
EPIC Negative/SURP-P High Pairs Versus EPIC Positive/SURP-P Low/Moderate Pairs
SURP-P
low/mod
EPIC

neg
pos

high
30
7
37

13
12
25

43
19
62

As shown in Figure 4, these survey counts demonstrated that 21% of the sample
screened high with the SURP-P tool and did not screen positive with the EPIC questionnaire,
as compared to 11% of the sample screening low or moderate with SURP-P and not
screening negative with EPIC. The bi-directional probability value in this case remained
insignificant, with a p value of .263, indicating no statistically significant discordance.
Therefore, this finding did not support the initial first hypothesis.
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Figure 4
Directional Discordance—SURP-P High

The second hypothesis assumed there would be directional discordance with more
EPIC negative and SURP-P moderate/high pairs than EPIC positive and SURP-P low pairs.
As shown in Table 3, the survey count showed EPIC negative and SURP-P moderate/high at
30, while EPIC positive and SURP-P low had a count of 0.
Table 3
EPIC Negative/SURP-P Moderate/High Pairs Versus EPIC Positive/SURP-P Low Pairs
SURP-P
low
EPIC

neg
pos

mod/high
13
30
0
19
13
49

43
19
62

As shown in Figure 5, these survey counts revealed a remarkable difference between
the two methods. Results demonstrated that 48% of the population who screened moderate or
high in SURP-P did not screen positive with the EPIC questionnaire, and 0% who screened
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low in SURP-P did not screen negative in EPIC. In this case, the bi-directional probability
value was significant, with a p value of less than .001. This indicates that statistically
significant directional discordance supported the second hypothesis.
Figure 5
Directional Discordance—SURP-P Moderate/High

Implications For Practice
These findings demonstrated several key points. First, the Fisher’s exact results
showed that the two screening methods were associated. This was evident in the initial
positive percentage findings, which demonstrated that as SURP-P went from low to moderate
to high, EPIC positive proportions increased steadily. As SURP-P increased, EPIC was more
likely to screen positive, indicating some association between the two measures. This
association was further evident with a p value finding of .006, indicating a significant
association between the SURP-P tool and the EPIC questionnaire. This validated that the two
methods attempt to screen for the same risk, supporting this study project comparison.
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Second, the EPIC positive and SURP-P low percentages produced a 0% result. In
contrast, the EPIC negative and SURP-P moderate percentages resulted in a 27% result, and
the EPIC negative and SURP-P high percentages resulted in a 21% result. This demonstrated
that SURP-P did not miss any screen that EPIC screened positive. This also demonstrated
that SURP-P indicated some follow-up should occur, while EPIC did not.
The most significant finding in the Fisher’s exact test comparing positive screenings
was that the SURP-P tool captured 79% of the population in screening positive with a
moderate- or high-risk result. In contrast, EPIC captured only about 31% of the population,
and individually SURP-P moderate (39%) and SURP-P high (40%) were similar in
comparison to the EPIC questionnaire. McNemar’s test supported SURP-P moderate and
high as the cutoff for screening, as evident in the bi-directional probability being significant;
this was not found with SURP-P high alone being the cutoff. When used properly, the SURPP tool recommends both moderate and high-risk categories have further follow-up. Clinicians
cannot solely depend on a SURP-P high positive result. They must be able to understand and
properly manage both SURP-P moderate- and high-risk results. The SURP-P tool gives
guidance clinicians can follow based on each result.
These findings also demonstrated that 48% of the population who screened moderate
or high in SURP-P did not screen positive with the EPIC questionnaire. This showed about
half the sample screened as having risk with SURP-P but were not detected as having risk
with EPIC. It also showed those who screened low in SURP-P also screened negative in
EPIC. Lastly, these results demonstrated that SURP-P did not fail to capture anyone that
EPIC might have caught.
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Overall, this pilot study project and use of the SURP-P screening tool built upon
current evidence-based research in substance abuse screening among the pregnant
population. Study results demonstrated that the well-validated, evidence-based SURP-P
screening tool captured a significantly greater number of pregnant women at risk for
substance abuse than the non-validated EPIC questionnaire. This study project also showed
that in addition to using such a tool, it is equally important for clinicians to be fully trained
and understand how to objectively interpret SURP-P screening results and provide proper
follow-up and management for those in pregnancy identified as at-risk for substance abuse.
Implementation
Because the focal organization’s women’s specialty program in this study project
does not have a comprehensive substance abuse screening program and management system
in place, several steps need to take place to achieve the short-term and long-term goals
proposed in this study project. First, it would be beneficial to adopt the SURP-P tool across
all providers who care for the pregnant population within the focal organization’s women’s
specialty program. Evidence in this study project strongly demonstrated that a significant
number of patients are being missed with the current Epic questionnaire and that the SURP-P
tool is an extremely effective tool for identifying pregnant patients at risk for substance
abuse.
These changes in care would impact current clinic workflow and coding and billing,
as well as clinician practice. A review of programs, resources, and materials related to
substance abuse would have to be conducted, and training on implementation would need to
be provided to both staff and clinicians. It would be important to secure staff buy-in by
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educating them on the goals of these changes being improving patient care and improving
maternal and fetal outcomes.
It could be practical to consider rolling out the SURP-P tool at the focal women’s
health clinic only, with future plans to implement it program-wide. The clinic would need to
ensure that this tool replaced the EPIC questionnaire in its entirety when screening the
pregnant population. Considering that EPIC is an electronic medical system for
documentation and SURP-P is a patient self-reporting instrument which has only been
studied in written form, it would be necessary to first have the tool administered to patients in
the usual fashion as discussed in this study project, and then the answers could be uploaded
into EPIC where scoring could be calculated (Yonkers, et al., 2010, ACOG, 2017). This
would provide ease of use, facilitate adoption of the tool, create integration into EPIC, and
reduce potential for error when administering the tool.
Second, there needs to be consensus on and standardization of the framework for
identifying and managing substance abuse in pregnancy. As they consider standardizing their
substance abuse management framework, the focal organization women’s specialty program
can utilize both the MIECHV modified SURP-P tool and the evidence-based guidelines
established by the WHO (2014). The MIECHV modified SURP-P tool, shown in Appendix
F, provides guidance for the scoring as well as a framework for how to manage patients
based on their scoring results. WHO guidelines provide 224 pages of detailed information on
the identification and management of substance use and substance use disorders in
pregnancy, including five key principles that should be followed:
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1) Prioritizing prevention: A multifaceted approach uses multidisciplinary action to
prevent, reduce, and cease the use of substance use during pregnancy and in the
postpartum period.
2) Ensuring access to prevention and treatment services: Affordable prevention and
treatment services and interventions should be accessible to all women and
families affected by substance abuse.
3) Respecting patient autonomy: Patients should be fully informed on the risks and
benefits of breastfeeding and substance abuse; available treatment options should
be reviewed, and patient autonomy should be respected as patients make decisions
regarding their own health and the health of their fetus.
4) Providing comprehensive care: It is critical that a comprehensive level of care be
matched with the complexity and multifaceted nature of the patient’s substance
abuse.
5) Safeguarding against discrimination and stigmatization: Standardized treatment
should be offered to all women in a way that is empathic, respectful, nonstigmatizing, and non-judgmental, with sensitivity to age, culture, and language
differences. Resources should be available in written, video, and oral formats in
patients’ preferred language and consistent their level of literacy. Clinicians must
take great sensitivity when private or distressing information is revealed by the
patient.
Rolling out this framework is likely to be demanding, as it must be extensive and
unique to the organization, specialty program, and patient population. This focal site of this
study project may not be ready for a full substance abuse management program. However, at
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a minimum they need to establish a framework and workflow for those identified as at-risk
for substance abuse; as it currently stands, identifying these patients is largely subjective and
based on individual providers’ interpretation of the EPIC questionnaire results.
The focal organization would benefit from creating a committee task force comprised
of the woman’s specialty program, maternal fetal medicine, and other key stakeholders to
ensure its success in developing their long-term goal of developing a full substance abuse
management program. Any such program would undoubtably warrant institutional policy
change and support within the focal organization to ensure in its long-term success.
Strengths and Weaknesses of the Study project
A strength of this study project was that both screening methods were administered in
printed format in one packet, paired the same way for each participant in the study project.
The study project was also anonymous, tracked only by numerical pairing to encourage
honest disclosure by participants. The study project also had a comprehensive methodology
for implementation and clear direction in research design and intended adoption.
A limitation of this study project was that it might not be generalizable because it was
a small study project within one specified clinic. This study project utilized a small
convenience sample, and participants were not randomly selected. Also, no sub-group
analysis was considered in this study project. The screening tools was administered in
English, which, although a requirement to participate in the study project, may have not been
participants’ primary language. A perception of disclosure risk may also have prevented
some respondents from giving an honest appraisal of their at-risk use.
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Conclusion
Pregnancy presents a unique opportunity for women to evaluate their patterns of
living, such as whether they are substance abusing and whether they will change those
patterns (WHO, 2014). Providers have limited opportunities to screen for such risks and
intervene with greatest impact (WHO, 2014). Having the proper substance abuse screening
tool in place will help clinicians avoid missed opportunities to intervene (Coleman-Cowger et
al., 2019).
It is the responsibility of every provider caring for this vulnerable population to
ensure that all women in pregnancy are being equally and comprehensively cared for,
regardless of socioeconomic status or cultural background. (WHO, 2014). Substance abuse in
pregnancy is a complex issue affecting the social, mental, and physical wellbeing of mothers,
babies, and families (WHO, 2014). It is important that proper support, care, and resources are
available in a manner that promotes the wellbeing of not only mothers and babies but also
family units and communities, thus preventing stigmatization, discrimination, and
marginalization (WHO, 2014.).
It is evident that a gap currently exists in evidence-based care in screening and
managing pregnant women at risk for substance abuse within the focal organization of this
study project. Fostering the adoption of a well-validated, evidence-based universal substance
abuse screening tool in a nondiscriminatory, routine manner is the necessary first step in
providing the optimal care necessary for this vulnerable population within this organization.
As evidence has shown, use of an evidence-based, universal substance abuse screening tool
contributes to improved maternal and fetal outcomes, and this has been demonstrated in this
study project.
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